Clinical Trial Update: A Study of Intravenous Vedolizumab Administered Every 4 Weeks in Japanese Participants With Moderate to Severe Ulcerative Colitis or Crohn's Disease [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating intravenous vedolizumab every 4 weeks in Japanese participants with moderate-to-severe ulcerative colitis or Crohn's disease; the study…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Crohn Disease
• Ulcerative Colitis

Drugs mentioned

• Vedolizumab (vedolizumab)

Snippet

Sponsor: Takeda | Conditions: Ulcerative Colitis, Crohn's Disease | Phase 3 | Status: ACTIVE_NOT_RECRUITING